Sanofi (NASDAQ:SNY) Shares Sold by TD Asset Management Inc

Key Points

• TD Asset Management Inc reduced its stake in Sanofi (NASDAQ:SNY) by 2.7%, now holding 467,537 shares valued at approximately $25.93 million.
• During the fourth quarter, several institutional investors, including Price T Rowe Associates and Point72 Asset Management, significantly increased their holdings in Sanofi, indicating a growing interest in the stock.
• Sanofi's shares have seen a trading range between $45.80 and $60.12 over the past year, with current analyst ratings reflecting a consensus of "Buy" and an average target price of $62.00.

TD Asset Management Inc trimmed its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 2.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 467,537 shares of the company's stock after selling 12,844 shares during the period. TD Asset Management Inc's holdings in Sanofi were worth $25,930,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in SNY. Golden State Wealth Management LLC grew its stake in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock valued at $62,000 after acquiring an additional 264 shares in the last quarter. Wayfinding Financial LLC acquired a new stake in shares of Sanofi during the first quarter valued at about $63,000. Finally, Tsfg LLC grew its stake in shares of Sanofi by 1,107.0% during the first quarter. Tsfg LLC now owns 1,207 shares of the company's stock valued at $67,000 after acquiring an additional 1,107 shares in the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

Sanofi stock traded up $1.11 during mid-day trading on Friday, hitting $46.75. The company's stock had a trading volume of 2,518,877 shares, compared to its average volume of 2,122,035. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $114.65 billion, a P/E ratio of 11.24, a P/E/G ratio of 1.05 and a beta of 0.48. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The stock's fifty day moving average price is $49.21 and its two-hundred day moving average price is $52.09.

Analysts Set New Price Targets

Several equities analysts have recently commented on SNY shares. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas started coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research report on Monday, June 2nd. Finally, Barclays reissued an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.